Mersana Therpts (NASDAQ:MRSN) posted its quarterly earnings data on Friday. The company reported ($6.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $5.77, Bloomberg Earnings reports. The firm had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $3.33 million.

Mersana Therpts (NASDAQ:MRSN) traded up 1.78% on Friday, hitting $15.42. The stock had a trading volume of 15,235 shares. The company’s market cap is $349.20 million. The stock’s 50-day moving average is $14.41 and its 200-day moving average is $14.41. Mersana Therpts has a 52-week low of $12.71 and a 52-week high of $15.87.

Several research analysts have recently weighed in on MRSN shares. Wedbush reissued an “outperform” rating and issued a $25.00 price objective on shares of Mersana Therpts in a research report on Monday, July 24th. J P Morgan Chase & Co started coverage on Mersana Therpts in a research report on Monday, July 24th. They issued an “overweight” rating and a $23.00 price objective for the company. Cowen and Company started coverage on Mersana Therpts in a research report on Monday, July 24th. They issued an “outperform” rating for the company. Finally, Leerink Swann started coverage on Mersana Therpts in a research report on Monday, July 24th. They issued an “outperform” rating and a $23.00 price objective for the company.

In related news, major shareholder M James Barrett acquired 1,000,000 shares of the stock in a transaction on Monday, July 3rd. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

An institutional investor recently bought a new position in Mersana Therpts stock. Vanguard Group Inc. acquired a new stake in Mersana Therpts (NASDAQ:MRSN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 75,000 shares of the company’s stock, valued at approximately $1,048,000. Vanguard Group Inc. owned about 0.33% of Mersana Therpts as of its most recent filing with the SEC. 35.99% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Mersana Therpts (NASDAQ:MRSN) Posts Quarterly Earnings Results, Misses Estimates By $5.77 EPS” was published by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/12/mersana-therpts-nasdaqmrsn-posts-quarterly-earnings-results-misses-estimates-by-5-77-eps.html.

Mersana Therpts Company Profile

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Receive News & Ratings for Mersana Therpts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therpts and related companies with MarketBeat.com's FREE daily email newsletter.